Vincristine Sulfate Liposome

  (vin-KRIS-teen SUL-fayt LY-poh-some)

This page contains brief information about vincristine sulfate liposome and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s):		Marqibo
FDA Approved:		Yes

FDA Approval for Vincristine Sulfate Liposome

Vincristine sulfate liposome is approved to treat:

• Acute lymphoblastic leukemia that is Philadelphia chromosome negative. It is used in patients whose disease has relapsed two or more times or has not gotten better with two or more types of treatment.

Vincristine sulfate liposome is also being studied in the treatment of other types of cancer.

Vincristine sulfate liposome is a form of vincristine sulfate contained inside liposomes (very tiny particles of fat). This form may work better than other forms of vincristine sulfate and have fewer side effects. Also, because its effects last longer in the body, it doesn't need to be given as often. For more information about vincristine sulfate that may apply to vincristine sulfate liposome, see the Drug Information Summary for Vincristine Sulfate.

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Find Clinical Trials for Liposomal Vincristine Sulfate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Back to Top